Takayuki Yamamoto1, Qi Li2, Hidetaka Hara1, Liaoran Wang2, Hongmin Zhou3, Juan Li2, Devin E Eckhoff1, A Joseph Tector1, Edwin C Klein4, Ray Lovingood5, Mohamed Ezzelarab4, David Ayares6, Yi Wang7, David K C Cooper1, Hayato Iwase8. 1. Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA; Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China. 3. Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Cardiothoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 4. Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA. 5. Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham, AL, USA. 6. Revivicor, Blacksburg, VA, USA. 7. Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China. 8. Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: hiwase@uabmc.edu.
Abstract
BACKGROUND: In the pig-to-baboon artery patch model with no immunosuppressive therapy, a graft from an α1,3-galactosyltransferase gene-knockout (GTKO) pig elicits a significant anti-nonGal IgG response, indicating sensitization to the graft. A costimulation blockade-based regimen, e.g., anti-CD154mAb or anti-CD40mAb, prevents sensitization. However, neither of these agents is currently FDA-approved. The aim of the present study was to determine the efficacy of FDA-approved agents on the T and B cell responses. METHODS: Artery patch xenotransplantation in baboons was carried out using GTKO/CD46 pigs with (n = 2) or without (n = 1) the mutant transgene for CIITA-knockdown. Immunosuppressive therapy consisted of induction with ATG and anti-CD20mAb, and maintenance with different combinations of CTLA4-Ig, tacrolimus, and rapamycin. In addition, all 3 baboons received daily corticosteroids, the IL-6R blocker, tocilizumab, at regular intervals, and the TNF-α blocker, etanercept, for the first 2 weeks. Recipient blood was monitored for anti-nonGal antibody levels by flow cytometry (using GTKO/CD46 pig aortic endothelial cells), and mixed lymphocyte reaction (MLR). CD22+B cell profiles (naïve [IgD+/CD27-], non-switched memory [IgD+/CD27+], and switched memory [IgD-/CD27+] B cell subsets) were measured by flow cytometry. At 6 months, the baboons were euthanized and the grafts were examined histologically. RESULTS: No elicited anti-pig antibodies developed in any baboon. The frequency of naïve memory B cells increased significantly (from 34% to 90%, p = 0.0015), but there was a significant decrease in switched memory B cells (from 17% to 0.5%, p = 0.015). MLR showed no increase in the proliferative T cell response in those baboons that had received CTLA4-Ig (n = 2). Histological examination showed few or no features of rejection in any graft. CONCLUSIONS: The data suggest that immunosuppressive therapy with only FDA-approved agents may be adequate to prevent an adaptive immune response to a genetically-engineered pig graft, particularly if CTLA4-Ig is included in the regimen, in part because the development of donor-specific memory B cells is inhibited.
BACKGROUND: In the pig-to-baboon artery patch model with no immunosuppressive therapy, a graft from an α1,3-galactosyltransferase gene-knockout (GTKO) pig elicits a significant anti-nonGal IgG response, indicating sensitization to the graft. A costimulation blockade-based regimen, e.g., anti-CD154mAb or anti-CD40mAb, prevents sensitization. However, neither of these agents is currently FDA-approved. The aim of the present study was to determine the efficacy of FDA-approved agents on the T and B cell responses. METHODS: Artery patch xenotransplantation in baboons was carried out using GTKO/CD46pigs with (n = 2) or without (n = 1) the mutant transgene for CIITA-knockdown. Immunosuppressive therapy consisted of induction with ATG and anti-CD20mAb, and maintenance with different combinations of CTLA4-Ig, tacrolimus, and rapamycin. In addition, all 3 baboons received daily corticosteroids, the IL-6R blocker, tocilizumab, at regular intervals, and the TNF-α blocker, etanercept, for the first 2 weeks. Recipient blood was monitored for anti-nonGal antibody levels by flow cytometry (using GTKO/CD46pig aortic endothelial cells), and mixed lymphocyte reaction (MLR). CD22+B cell profiles (naïve [IgD+/CD27-], non-switched memory [IgD+/CD27+], and switched memory [IgD-/CD27+] B cell subsets) were measured by flow cytometry. At 6 months, the baboons were euthanized and the grafts were examined histologically. RESULTS: No elicited anti-pig antibodies developed in any baboon. The frequency of naïve memory B cells increased significantly (from 34% to 90%, p = 0.0015), but there was a significant decrease in switched memory B cells (from 17% to 0.5%, p = 0.015). MLR showed no increase in the proliferative T cell response in those baboons that had received CTLA4-Ig (n = 2). Histological examination showed few or no features of rejection in any graft. CONCLUSIONS: The data suggest that immunosuppressive therapy with only FDA-approved agents may be adequate to prevent an adaptive immune response to a genetically-engineered pig graft, particularly if CTLA4-Ig is included in the regimen, in part because the development of donor-specific memory B cells is inhibited.
Authors: M M Mohiuddin; P C Corcoran; A K Singh; A Azimzadeh; R F Hoyt; M L Thomas; M A Eckhaus; C Seavey; D Ayares; R N Pierson; K A Horvath Journal: Am J Transplant Date: 2011-11-09 Impact factor: 8.086
Authors: Mohamed B Ezzelarab; Burcin Ekser; Kumiko Isse; Hayato Iwase; Adrian E Morelli; David Ayares; David K C Cooper Journal: Transplantation Date: 2014-03-15 Impact factor: 4.939
Authors: Christopher G A McGregor; Davide Ricci; Naoto Miyagi; Paul G Stalboerger; Zeji Du; Elise A Oehler; Henry D Tazelaar; Guerard W Byrne Journal: Transplantation Date: 2012-04-15 Impact factor: 4.939
Authors: Hidetaka Hara; Naoko Koike; Cassandra Long; Jordan Piluek; Danny S Roh; Nirmala SundarRaj; James L Funderburgh; Yoshiaki Mizuguchi; Kumiko Isse; Carol J Phelps; Suyapa F Ball; David L Ayares; David K C Cooper Journal: Invest Ophthalmol Vis Sci Date: 2011-07-15 Impact factor: 4.799
Authors: Sumeet S Teotia; Randall C Walker; Johannes M Schirmer; Henry D Tazelaar; Marian G Michaels; Jack M Risdahl; Guerard W Byrne; John S Logan; Christopher G A McGregor Journal: Xenotransplantation Date: 2005-03 Impact factor: 3.907
Authors: Mohamed B Ezzelarab; Burcin Ekser; Gabriel Echeverri; Hidetaka Hara; Corin Ezzelarab; Cassandra Long; Pietro Bajona; Bertha Garcia; Noriko Murase; David Ayares; David K C Cooper Journal: Xenotransplantation Date: 2012 Jul-Aug Impact factor: 3.907
Authors: Muhammad M Mohiuddin; Avneesh K Singh; Philip C Corcoran; Marvin L Thomas Iii; Tannia Clark; Billeta G Lewis; Robert F Hoyt; Michael Eckhaus; Richard N Pierson Iii; Aaron J Belli; Eckhard Wolf; Nikolai Klymiuk; Carol Phelps; Keith A Reimann; David Ayares; Keith A Horvath Journal: Nat Commun Date: 2016-04-05 Impact factor: 14.919
Authors: Abhijit Jagdale; Huy Nguyen; Hayato Iwase; Jeremy B Foote; Takayuki Yamamoto; Mariyam Javed; David Ayares; Douglas J Anderson; Devin E Eckhoff; David K C Cooper; Hidetaka Hara Journal: Transpl Immunol Date: 2022-01-31 Impact factor: 2.032
Authors: Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase Journal: Data Brief Date: 2018-09-13